NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD
ADMA Biologics (NASDAQ:ADMA) shows strong growth fundamentals and a technical breakout setup, making it a stock to watch in the biotech sector.
ADMA Biologics (NASDAQ:ADMA) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has outperformed peers and may present a breakout opportunity.
ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.
Style Box ETF report for XSHQ
ADMA Biologics (NASDAQ:ADMA) shows strong growth, reasonable valuation, and solid financial health, making it an attractive candidate for investors seeking affordable growth stocks in the biotech sector.
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
Mentions: GRFS
Investors need to pay close attention to ADMA Biologics stock based on the movements in the options market lately.
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.
VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.
The company makes immunoglobulin products using donated plasma.
Mentions: HIMS
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Adma Biologics (ADMA) delivered earnings and revenue surprises of -12.50% and 3.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BHST
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51%...
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. Stock down.
Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.
Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.
Mentions: AGL
Zacks.com users have recently been watching Adma Biologics (ADMA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.